Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients

British Journal of Clinical Pharmacology

Volumn 65, Issue 4, 2008, Pages 548-557

  Hirt, Déborah ^a,b,e   Mentré, France ^c,d   Tran, Agnès ^a   Rey, Elisabeth ^a   Auleley, Solange ^c   Salmon, Dominique ^d   Duval, Xavier ^a,c,d   Tréluyer, Jean Marc ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d BICHAT HOSPITAL   (France)

^e Paris Descartes University   (France)

Author keywords

CYP2C19; HIV; Nelfinavir; NONMEM; Pharmacokinetics

Indexed keywords

CHOLESTEROL; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GLUCOSE; LAMIVUDINE PLUS ZIDOVUDINE; MULTIDRUG RESISTANCE PROTEIN 1; NELFINAVIR; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG TRANSFORMATION; ENZYME POLYMORPHISM; FEMALE; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

ADULT; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; BODY WEIGHT; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; NELFINAVIR; POLYMORPHISM, GENETIC; TREATMENT OUTCOME; VIRAL LOAD;

EID: 40549144409     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.03039.x     Document Type: Article

References (26)

1. Palella FJ Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigations. N Engl J Med 1998 338 : 853 60.
2. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ Feinberg JE, Balfour HH Deyton LR, Chodakewitz JA, Fischl MA. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997 337 : 725 33.
3. Viracept package insert, 2001; Agouron Pharmaceuticals, La Jolla, CA, USA.
4. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998 101 : 289 94.
5. Lillibridge JH, Lee CA, Pithavala YK. The role of polymorphic CYP2C19 in the metabolism of nelfinavir mesylate. In : XII Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists. Arlington, VA : American Association of Pharmaceutical Scientists, 1998 Abstract 3035. Available at http://www.aapspharmsci.org/abstracts/AM_1998/1156.html (last accessed: 27 September 2007).
6. Zhang KE, Wu E, Patick AK, Kerr B, Zorbas M, Lankford A, Kobayashi T, Maeda Y, Shetty B, Webber S. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrob Agents Chemother 2001 45 : 1086 93.
7. Tran A, Jullien V, Alexandre J, Rey E, Rabillon F, Girre V, Dieras V, Pons G, Goldwasser F, Tréluyer JM. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 2006 79 : 570 80.
8. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, Koch I, Zibat A, Brockmoller J, Halpert JR, Zanger UM, Wojnowski L. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001 11 : 773 9.
9. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, Retelska D, Ruiz L, Schinkel AH, Vernazza P, Eap CB, Telenti A, Swiss HIV Cohort Study. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002 359 : 30 6.
10. Saitoh A, Singh KK, Powell CA, Fenton T, Fletcher CV, Brundage R, Starr S, Spector SA. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS 2005 19 : 371 80.
11. Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, De Gruttola V, Pollard RB, Merigan TC, Hirsch MS, George AL Donahue JP, Kim RB. Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis 2005 192 : 1931 42.
12. Burger DM, Schwietert HR, Colbers EP, Becker M. The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavir. Br J Clin Pharmacol 2006 62 : 250 2.
13. Kaeser B, Charoin JE, Gerber M, Oxley P, Birnboeck H, Saiedabadi N, Banken L. Assessment of the bioequivalence of two nelfinavir tablet formulations under fed and fasted conditions in healthy subjects. Int J Clin Pharmacol Ther 2005 43 : 154 62.
14. De Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994 46 : 594 8.
15. Dally H, Edler L, Jager B, Schmezer P, Spiegelhalder B, Dienemann H, Drings P, Schulz V, Kayser K, Bartsch H, Risch A. The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose. Pharmacogenetics 2003 13 : 607 18.
16. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001 69 : 169 74.
17. Beal SL, Sheiner LB. NONMEM User's Guide. University of California at San Francisco : NONMEM Project Group, 1998.
18. Ihaka R, Gentleman R. R: a language for data analysis and graphics. J Comput Graphic Stat 1996 5 : 299.
19. Panhard X, Goujard C, Legrand M, Taburet AM, Diquet B, Mentré F, COPHAR 1-ANRS Study Group. Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART. Br J Clin Pharmacol 2005 60 : 390 403.
20. Hirt D, Treluyer JM, Jullien V, Firtion G, Chappuy H, Rey E, Pons G, Mandelbrot L, Urien S. Pregnancy-related effects on nelfinavir and M8 pharmacokinetics: a population study in 133 women. Antimicrob Agents Chemother 2006 50 : 2079 86.
21. Jackson KA, Rosenbaum SE, Kerr BM, Pithavala YK, Yuen G, Dudley MN. A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a phase III clinical trial. Antimicrob Agents Chemother 2000 44 : 1832 7.
22. Hirt D, Urien S, Jullien V, Firtion G, Rey E, Pons G, Blanche S, Treluyer JM. Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children. Antimicrob Agents Chemother 2006 50 : 910 6.
23. Powderly WG, Saag MS, Chapman S, Yu G, Quart B, Clendeninn NJ. Predictors of optimal virological response to potent antiretroviral therapy. AIDS 1999 13 : 1873 80.
24. Hoetelmans RM, Reijers MH, Weverling GJ, ten Kate RW, Wit FW, Mulder JW, Weigel HM, Frissen PH, Roos M, Jurriaans S, Schuitemaker H, de Wolf F, Beijnen JH, Lange JM. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS 1998 12 : F111 5.
25. Periard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, Marcovina SM, Glauser MP, Nicod P, Darioli R, Mooser V. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999 100 : 700 5.
26. Reijers MH, Weigel HM, Hart AA, Ten Kate RW, Mulder JW, Reiss P, Schuitemaker H, Hoetelmans RM, Weverling GJ, Lange JM. Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study. AIDS 2000 14 : 59 67.